( MENAFN - Investor Brand Network) Annovis Bio (NYSE: ANVS) , a late-stage, clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer's disease (“AD”) and Parkinson's disease (“PD”) will host an investor webcast. According to the announcement, during the webcast, Annovis Bio officials will discuss recent advancements in the development of Buntanetap, the company's lead drug candidate, as well as strategic plans for upcoming clinical trials and an overview of the company's progress along with its future direction. The call is slated for June 11, 2024, at 4:30 p.
m. ET. Buntanetap has been formulated to target neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein and TDP43.
By improving synaptic transmission and axonal transport while also reducing neuroinflammation, the drug works to reverse neurodegeneration in AD, PD and other neurodegenerative diseases. To view the full webcast, visit To view the full press release, visit About Annovis Bio Inc. Annovis Bio is headquartered in Malvern, Pennsylvania, and is dedicated to addressing neurodegeneration in diseases such as AD and PD.
The company's innovative approach targets multiple neurotoxic proteins, aiming to restore brain function and improve the quality of life for patients. For more information about the company, visit . About BioMedWire BioMedWire (“BMW”) is a specialized communicatio.
